معرفی
Professor Stephen Mulligan is an Adjunct Professor at the Northern Clinical School within the Sydney Medical School, University of Sydney. His academic role focuses on haematological malignancies, particularly Chronic Lymphocytic Leukaemia (CLL). He has extensive expertise in clinical trials, immunology, and proteomics, with a strong emphasis on translational research. His work spans drug development, molecular mechanisms of disease, and patient management strategies in oncology.
Research Interests: Professor Mulligan's research is centered on CLL pathogenesis, treatment resistance, and improving patient outcomes through novel therapeutics. His work integrates clinical practice with laboratory research, addressing challenges such as immune dysfunction and drug resistance in haematological disorders. He has contributed to pivotal studies on BTK inhibitors (e.g., ibrutinib) and venetoclax, evaluating their efficacy and mechanisms in CLL and related conditions.
Publications & Grants: With over 100 peer-reviewed articles, his work spans topics like vaccine response in immunocompromised patients, genetic drivers of CLL relapse, and comparative efficacy of targeted therapies. Notable grants include studies on immunoglobulin replacement therapy and phase III trials comparing zanubrutinib vs ibrutinib in Waldenström macroglobulinemia. His contributions include defining diagnostic criteria for monoclonal B-cell lymphocytosis and advancing understanding of CLL's microenvironmental interactions.
Awards & Recognition: While no specific awards are listed, his sustained research output and leadership in clinical trials reflect significant contributions to the field of haematology.
Labs & Collaborations: His research is conducted within the Sydney Medical School’s clinical and translational research frameworks, collaborating with institutions like the Leukaemia Foundation of Australia and international groups (e.g., ERIC consortium). Key collaborations include studies on second primary malignancies in CLL patients and skin cancer surveillance strategies.
